Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease

Abstract Background and objective Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder after Alzheimer's disease. The aim of this work was to determine whether the differences of serum miRNAs profiling could distinguish PD patients from healthy individu...

Full description

Saved in:
Bibliographic Details
Published in:Parkinsonism & related disorders 2016-01, Vol.22, p.68-73
Main Authors: Ding, Haixia, Huang, Zhen, Chen, Mengjie, Wang, Cheng, Chen, Xi, Chen, Jiangning, Zhang, Junfeng
Format: Article
Language:English
Subjects:
Adult
Aged
Area Under Curve
Biomarkers - blood
Case-Control Studies
Down-Regulation
Female
Humans
Male
MicroRNAs - blood
Middle Aged
Neurology
Parkinson Disease - blood
Parkinson Disease - diagnosis
Parkinson's disease
Real-Time Polymerase Chain Reaction
ROC Curve
Sensitivity and Specificity
Serum miRNA
Transcriptome
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background and objective Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder after Alzheimer's disease. The aim of this work was to determine whether the differences of serum miRNAs profiling could distinguish PD patients from healthy individuals. Methods We collected serum samples from 106 sporadic PD patients and 91 age/gender-matched healthy controls. Serum miRNAs were analysed by Solexa sequencing followed by a qRT-PCR examination. The qRT-PCR assay, which was divided into two phases, was used to validate the expression of miRNAs screened by Solexa sequencing. Receiver operating characteristic (ROC) curve analysis and clustering analysis were performed to determine the diagnostic usefulness of the selected miRNAs for PD. Results In this study, we generated a profile of 5 serum miRNAs: miR-195 was up-regulated, and miR-185, miR-15b, miR-221 and miR-181a were down-regulated. Conclusion This group of five miRNAs can precisely distinguish PD patients from health individuals and may be used as a potential serum-based biomarker for the diagnosis of PD.
ISSN:1353-8020
1873-5126
DOI:10.1016/j.parkreldis.2015.11.014